NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) is an Australian drug development company developing novel peptide-based pharmaceutical products that target a number of neurodegenerative conditions with high unmet medical need. Therapeutic indications include Alzheimer’s Disease, Multiple Sclerosis, Glaucoma and Post-Covid Lung Fibrosis. The companies lead compound, EmtinB works by effectively slowing down the death of dying cells and regenerating damaged nerves and tissue fibres. NeuroScientific Biopharmaceuticals is committed to a research and development program that is methodically planned, efficiently executed and risk aware. www.neuroscientific.com